1-5 of 5
Jocelyn Staunton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

Free
Peggy A. Thompson, Boreth Eam, Nathan P. Young, Sarah Fish, Joan Chen, Maria Barrera, Haleigh Howard, Eric Sung, Ana Parra, Jocelyn Staunton, Gary G. Chiang, Adina Gerson-Gurwitz, Christopher J. Wegerski, Andres Nevarez, Jeff Clarine, Samuel Sperry, Alan Xiang, Christian Nilewski, Garrick K. Packard, Theodore Michels, Chinh Tran, Paul A. Sprengeler, Justin T. Ernst, Siegfried H. Reich, Kevin R. Webster
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (1): 26–36.
https://doi.org/10.1158/1535-7163.MCT-19-0973
Published: 05 January 2021
View articletitled, Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A
Open the PDF for Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A in another window
Includes: Supplementary data
Journal Articles

Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers

Free
Peggy A Thompson, Nathan P Young, Craig R Stumpf, Boreth Eam, Vikas K Goel, Joan Chen, Sarah Fish, Gregory S Parker, Adina Gerson-Gurwitz, Maria Barrera, Eric Sung, Jocelyn Staunton, Gary G Chiang, Christopher J Wegerski, Samuel Sperry, Kevin R Webster, Siegfried H Reich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B133.
https://doi.org/10.1158/1535-7163.TARG-19-B133
Published: 01 December 2019
View articletitled, Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers
Journal Articles

Abstract A172: INK128, an orally active TORC1/2 kinase inhibitor, displays enhanced efficacy when combined with cytotoxic agents.

Free
Linda Kessler, Katti Jessen, Matthew Janes, Jocelyn Staunton, Jeff Kucharski, Xin Guo, Marikka Elia, Urmi Banerjee, Lucy Lan, Shunyou Wang, Josh Stewart, Angelina Luzader, Levan Darjania, Liansheng Li, Katrina Chan, Michael Martin, Pingda Ren, Christian Rommel, Yi Liu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A172.
https://doi.org/10.1158/1535-7163.TARG-11-A172
Published: 12 November 2011
View articletitled, Abstract A172: INK128, an orally active TORC1/2 kinase inhibitor, displays enhanced efficacy when combined with cytotoxic agents.
Journal Articles

Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.

Free
Katti Jessen, Linda Kessler, Jeff Kucharski, Xin Guo, Jocelyn Staunton, Matthew Janes, Marikka Elia, Urmi Banerjee, Lucy Lan, Shunyou Wang, Josh Stewart, Angelina Luzader, Levan Darjania, Liansheng Li, Katrina Chan, Mike Martin, Pingda Ren, Christian Rommel, Yi Liu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A171.
https://doi.org/10.1158/1535-7163.TARG-11-A171
Published: 12 November 2011
View articletitled, Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.
Journal Articles

Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity

Free
Katayoun Jessen, Shunyou Wang, Linda Kessler, Xin Guo, Jeff Kucharski, Jocelyn Staunton, Lucy Lan, Marikka Elia, Josh Stewart, Jolene Brown, Liansheng Li, Katrina Chan, Michael Martin, Pingda Ren, Christian Rommel, Yi Liu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B148.
https://doi.org/10.1158/1535-7163.TARG-09-B148
Published: 10 December 2009
View articletitled, Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity